It is time to define metabolically obese but normal‐weight (MONW) individuals
J. López-Miranda,P. Pérez-Martínez
DOI: https://doi.org/10.1111/cen.12181
2013-09-01
Clinical Endocrinology
Abstract:Obesity represents one of today’s major health problems and has reached epidemic proportions with an increased risk of premature death due to the significantly increased risk of developing type 2 diabetes (T2DM), hypertension, cardiovascular diseases (CVD), several types of cancer and metabolic disorders. One key issue in the area of obesity is gaining a greater understanding of its subtypes. Interestingly, not all obese individuals display a clustering of metabolic and cardiovascular risk factors, and likewise, not all lean individuals present a healthy metabolic and disease-free profile. In the 1980s, several investigators began to identify the existence of different subtypes of obesity. To date, there is no uniform definition for obesity phenotypes. Generally, metabolically healthy obesity (MHO) describes the absence of any overt cardiometabolic disease, in particular, T2DM, dyslipidaemia and hypertension in an individual with a body mass index >30 kg/m. In the absence of overt pathologies, the associations and clustering of cardiometabolic risk factors, such as metabolic syndrome (MetS) components or inflammatory markers, have also been used to categorize subjects as metabolically normal or abnormal. The adverse metabolic effects of obesity may partly be mediated by the close relationship between obesity and insulin resistance. However, obesity does not necessarily lead to insulin resistance and increased risk of metabolic comorbidities, as is shown by the fact that a subgroup of obese individuals can remain insulin sensitive and metabolically healthy. The prevention and treatment of obesity is a daunting medical and socioeconomic task and will not always be successful. Therefore, it is important to distinguish early on obese subjects who will benefit the most from losing weight (‘unhealthy obesity’) from MHO individuals who may not significantly improve their obesity-related metabolic risk by antiobesity treatment strategies. In contrast, metabolically obese but normal-weight (MONW) individuals are characterized by hyperinsulinism and insulin resistance and are vulnerable to T2DM and CVD, even though they are not obese. Furthermore, MONW subjects present altered insulin sensitivity, a higher level of visceral adiposity, a more atherogenic lipid profile and lower physical activity energy expenditure, which together confer an increased risk of cardiometabolic disease. However, there are still difficulties in discriminating MONW subjects from metabolically healthy subjects in clinical practice. A scoring method for identifying an MONW individual was proposed by Ruderman et al. based on the presence of hyperglycaemia, hypertriglyceridaemia, essential hypertension, polycystic ovaries, premature coronary heart disease, hyperuricaemia, family history, low birth weight, inactivity, evidence of mild obesity or central adiposity, and ethnicity. However, the usefulness of this idea has not yet been validated. In this issue of Clinical Endocrinology, Choi KM et al. have studied the impact of body mass index (BMI) and the presence of MetS on all-cause and cardiovascular mortality in elderly Korean men and women. In addition, they compared MONW and MHO subjects. A total of 2317 elderly people were studied using data from the south-west Seoul prospective cohort study. They found that, unlike MHO subjects, elderly individuals with the MONW phenotype exhibited greater all-cause mortality during the 10 years of follow-up. This finding supports the notion about the importance for predicting mortality of identifying the presence of cardiometabolic risk factors in older adults. At present, there is debate over whether or not MHO and MONW individuals have an increased risk of complications. Few studies have examined whether the MHO phenotype is associated with an increased CVD risk or mortality. Meigs et al. found that MHO individuals do not have an increased risk of incident diabetes and CVD. Similarly, St-Pierre et al. showed that obese men with fewer than three components of insulin resistance syndrome were not at increased risk of ischaemic heart disease. In addition, two other studies reported that MHO individuals do not show a greater all-cause mortality risk than insulin-sensitive normal-weight individuals. However, two recent studies found that obesity, even in the absence of metabolic alterations, is associated with an increased all-cause mortality risk. Furthermore, there is no consistent evidence to date on mortality and clinical consequences in MONW subjects, although a recent 6-year follow-up study reported a greater heart failure risk in MONW subjects compared with MHO individuals. To provide a conclusive answer to this question, large-scale longitudinal studies are needed. Moreover, *Please see related paper on pages 364–370 of this issue.